Results 1 to 10 of about 2,318,494 (246)

Immune Checkpoint Inhibitors in Cancer Therapy

open access: yesCurrent Oncology, 2022
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and
Yavar Shiravand   +8 more
openaire   +6 more sources

Negative Immune Checkpoint Inhibitors

open access: yesPharmaceutics
Checkpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate cancer cells or pathogens, primarily through the activation of T lymphocytes.
Magda Drewniak-Świtalska   +2 more
openaire   +4 more sources

SnapShot: Immune Checkpoint Inhibitors

open access: yesCancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Cardiotoxicity of immune checkpoint inhibitors

open access: yesESMO Open, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA   +7 more
openaire   +3 more sources

Immune Checkpoint Inhibitor–Induced Lipodystrophy

open access: yesJAMA Dermatology
This case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.
Riganti J.   +15 more
openaire   +3 more sources

Immune Checkpoint Inhibitors in Penile Cancer

open access: yesFuture Science OA, 2021
Carlo Buonerba   +9 more
openaire   +3 more sources

Immune checkpoint inhibitor-related endocrinopathies

open access: yesJournal of Translational Internal Medicine, 2022
Lu, Difei, Gao, Ying
openaire   +2 more sources

Immune Checkpoint Inhibitor-Induced Pancreatitis. [PDF]

open access: yesUnited European Gastroenterol J
Moro CF   +9 more
europepmc   +1 more source

Immune checkpoint inhibitor-associated cardiotoxicity: incidence, diagnosis, and management. [PDF]

open access: yesSupport Care Cancer
Haddad SF   +11 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review. [PDF]

open access: yesClin Med Insights Oncol
Al-Mashdali AF   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy